These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 36937282)
21. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351). Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836 [TBL] [Abstract][Full Text] [Related]
25. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Atmar RL; Finch N Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759 [TBL] [Abstract][Full Text] [Related]
26. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645 [TBL] [Abstract][Full Text] [Related]
27. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301 [TBL] [Abstract][Full Text] [Related]
28. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796 [TBL] [Abstract][Full Text] [Related]
31. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types. Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744 [TBL] [Abstract][Full Text] [Related]
32. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385 [TBL] [Abstract][Full Text] [Related]
33. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
34. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. Hau RK; Wright SH; Cherrington NJ Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633 [TBL] [Abstract][Full Text] [Related]
35. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. Soriano V; de-Mendoza C; Edagwa B; Treviño A; Barreiro P; Fernandez-Montero JV; Gendelman HE AIDS Rev; 2022 Mar; 24(1):41-49. PubMed ID: 35073629 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential. Martinez DR; Moreira FR; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Catanzaro N; Yount B; Baric TJ; Mallory ML; Conrad H; May SR; Dong S; Scobey DT; Montgomery SA; Perry J; Babusis D; Barrett KT; Nguyen AH; Nguyen AQ; Kalla R; Bannister R; Bilello JP; Feng JY; Cihlar T; Baric RS; Mackman RL; Schäfer A; Sheahan TP bioRxiv; 2023 Jun; ():. PubMed ID: 37425890 [TBL] [Abstract][Full Text] [Related]
37. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809 [TBL] [Abstract][Full Text] [Related]
39. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668 [TBL] [Abstract][Full Text] [Related]
40. Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. Bodie NM; Hashimoto R; Connolly D; Chu J; Takayama K; Uhal BD Antib Ther; 2023 Jan; 6(1):59-74. PubMed ID: 36741194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]